Liječnički vjesnik, Vol. 141 No. 7-8, 2019.
Pregledni rad
https://doi.org/10.26800/LV-141-7-8-31
Prognostic factors in myelodysplastic syndromes: single-center experience
Vibor Milunović
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb
Inga Mandac Rogulj
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb
Dražen Perica
; Medicinski fakultet u Zagrebu, Sveučilište u Zagrebu
Karla Mišura Jakobac
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb
Njetočka Gredelj Šimec
Anita Škrtić
; Medicinski fakultet u Zagrebu, Sveučilište u Zagrebu; zavod za patologiju i citologiju, Klinička bolnica Merkur, Zagreb
Ika Kardum-Skelin
; Medicinski fakultet u Zagrebu, Sveučilište u Zagrebu;Zavod za kliničku citologiju i citogenetiku, Klinička bolnica Merkur, Zagreb
Sanja Davidović Mrsić
; Klinički zavod za laboratorijsku dijagnostiku, Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zagreb
Slobodanka Ostojić Kolonić
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb; Medicinski fakultet u Zagrebu, Sveučilište u Zagrebu
Sažetak
Introduction: Myelodysplastic syndrome (MDS) is one of the most common myeloid neoplasms of elderly characterized by cytopenias and limited therapeutic options. The main aim of this retrospective singlecenter study was to examine the value of classical prognostic factors. The main outcome of the study was overall survival (OS) defined as death from MDS or any other reason. Methods: We analyzed the medical records of patients diagnosed with MDS at single centre in the period from beginning of 2013 to the end of 2016. Results:
Total of 58 patients (median age of diagnosis being 69 years) were included in the study. After median of follow-up of 12 months, median OS was 17 months and estimated 3-year OS rate 25%. Classical prognostic systems such as IPSS, WPSS and R-IPSS were statistically significant prognostic factors discriminating adequately between low and high risk groups in terms of outcome. However , due to small sample size, we were not able to distinguish the most appropriate scoring system. The cytogenetics subgroups according to IPPS and R-IPSS were significant predictors of outcomes underlying its crucial role in MDS diagnosis. Despite the statistical tendency morphological features of MDS (2008 World Health Organization subtype and number of blasts in bone marrow) were not significant predictors of OS. Among clinical features, only presence and degree of anemia and transfusion dependency were significant predictors of inferior survival. Conclusion: The majority of traditional prognostic factors were significant in our cohort in concordance with literature review.
Ključne riječi
MYELODYSPLATIC SYNDROMES – blood, classsification, genetics, mortality; CYTOGENETIC ANALYSIS; INTERNATIONAL CLASSIFICATION OF DISEASES; ANEMIA – complications; SURVIVAL ANALYSIS; RISK FACTORS; PROGNOSIS
Hrčak ID:
225771
URI
Datum izdavanja:
27.9.2019.
Posjeta: 4.336 *